Stryker Corp's Fletcher Robert S Sells 1,785 Shares at $393.07 on 2025-08-20.
ByAinvest
Thursday, Aug 21, 2025 4:40 pm ET1min read
SYK--
The stock price of SYK rose 2.18% on August 19, 2025, with a trading volume of $660 million, a 56% increase from the previous day [2]. However, the stock has since seen a 3.8% drop due to the underperformance of the Orthopaedics segment. Analysts forecast a 10.8% year-over-year earnings growth for FY2025, with a consensus "Moderate Buy" rating, despite a PEG ratio of 2.75 signaling potential overvaluation [2].
Institutional investors have also shown mixed activity in their holdings of SYK. Credit Agricole S A lowered its stake by 22.4% in the first quarter, while Banco Bilbao Vizcaya Argentaria S.A. boosted its holdings by 11.7% [1]. Other institutional investors, including BI Asset Management Fondsmaeglerselskab A S and Legacy Financial Advisors Inc., also adjusted their stakes in the company [1].
The insider sale by Fletcher Robert S is significant, as it represents a 5.84% decrease in his ownership of the stock, following the completion of the transaction [1]. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the provided hyperlink [1].
References:
[1] https://www.marketbeat.com/instant-alerts/filing-credit-agricole-s-a-sells-154008-shares-of-stryker-corporation-syk-2025-08-19/
[2] https://www.ainvest.com/news/stryker-shares-climb-2-18-660m-trading-volume-spike-56-higher-prior-day-mixed-earnings-results-2508/
Stryker Corporation (SYK) has announced that Fletcher Robert S, Vice President and Chief Legal Officer, has sold 1785 shares at a price of $393.07 per share on August 20, 2025.
Stryker Corporation (SYK) has seen a significant insider sale as Fletcher Robert S, Vice President and Chief Legal Officer, sold 1785 shares at a price of $393.07 per share on August 20, 2025 [1]. This sale comes amidst mixed Q2 2025 earnings results, where the company reported an adjusted EPS of $3.13 and revenue of $6.02 billion, despite a 97.2% decline in spinal implant sales within the Orthopaedics segment [2].The stock price of SYK rose 2.18% on August 19, 2025, with a trading volume of $660 million, a 56% increase from the previous day [2]. However, the stock has since seen a 3.8% drop due to the underperformance of the Orthopaedics segment. Analysts forecast a 10.8% year-over-year earnings growth for FY2025, with a consensus "Moderate Buy" rating, despite a PEG ratio of 2.75 signaling potential overvaluation [2].
Institutional investors have also shown mixed activity in their holdings of SYK. Credit Agricole S A lowered its stake by 22.4% in the first quarter, while Banco Bilbao Vizcaya Argentaria S.A. boosted its holdings by 11.7% [1]. Other institutional investors, including BI Asset Management Fondsmaeglerselskab A S and Legacy Financial Advisors Inc., also adjusted their stakes in the company [1].
The insider sale by Fletcher Robert S is significant, as it represents a 5.84% decrease in his ownership of the stock, following the completion of the transaction [1]. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the provided hyperlink [1].
References:
[1] https://www.marketbeat.com/instant-alerts/filing-credit-agricole-s-a-sells-154008-shares-of-stryker-corporation-syk-2025-08-19/
[2] https://www.ainvest.com/news/stryker-shares-climb-2-18-660m-trading-volume-spike-56-higher-prior-day-mixed-earnings-results-2508/

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet